Lunasin abrogates the expression of matrix metalloproteinases and reduction of type II collagen
Source abstract
Abstract
Impairment of type II collagen caused by MMPs in response to overproduction of IL-1β is an important step in the pathological progression of osteoarthritis (OA). Lunasin, a well-known peptide present in the soybean, has displayed a positive impact on numerous physiological functions. Little information in the effects of lunasin on cartilage degradation has been sought in clinical research before. Here, we report that lunasin suppressed the increase in MMP-3 and MMP-13 caused by IL-1β. In addition, we found that lunasin could prevent the decrease in TIMP-1 and TIMP-2 expressions caused by IL-1β. Notably, lunasin suppressed reduction of type II collagen, the basis for articular cartilage. Lunasin also attenuated activation of the JAK2/STAT1/IRF-1 pathway. These effects of lunasin suggest that it might become a promising therapeutic agent for chondro-protective therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Protein Hydrolysis and Bioactive Peptides · Natural product bioactivities and synthesis · Protease and Inhibitor Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopedic, Weifang Yidu Central Hospital
Department of Orthopedic, Weifang People’s Hospital
References (33)
Show source-provided references
1. 10.4062/biomolther.2014.02010.4062/biomolther.2014.020 ↗
2. 10.1016/j.clim.2012.12.01110.1016/j.clim.2012.12.011 ↗
3. 10.1002/jor.2268110.1002/jor.22681 ↗
4. 10.4238/2015.December.23.1510.4238/2015.December.23.15 ↗
5. 10.1172/JCI11847510.1172/JCI118475 ↗
6. 10.22203/eCM.v012a1110.22203/eCM.v012a11 ↗
7. 10.1038/srep2610610.1038/srep26106 ↗
8. 10.1038/867610.1038/8676 ↗
9. 10.3390/nu1009121110.3390/nu10091211 ↗
10. 10.1016/j.foodres.2018.12.02910.1016/j.foodres.2018.12.029 ↗
11. 10.1016/j.bbrc.2009.10.05310.1016/j.bbrc.2009.10.053 ↗
12. 10.1080/21691401.2016.117544410.1080/21691401.2016.1175444 ↗
13. 10.1080/21691401.2017.130440210.1080/21691401.2017.1304402 ↗
14. 10.2144/97221bi0110.2144/97221bi01 ↗
15. 10.1111/j.1471-4159.2011.07581.x10.1111/j.1471-4159.2011.07581.x ↗
16. 10.1016/j.bbapap.2011.06.02010.1016/j.bbapap.2011.06.020 ↗
17. 10.2741/181710.2741/1817 ↗
18. 10.1007/s00011-009-0112-910.1007/s00011-009-0112-9 ↗
19. 10.1186/ar201310.1186/ar2013 ↗
20. 10.2174/13894500777994009810.2174/138945007779940098 ↗
21. 10.1172/JCI11421510.1172/JCI114215 ↗
22. 10.3892/etm.2014.175010.3892/etm.2014.1750 ↗
23. 10.1002/mnfr.20120030110.1002/mnfr.201200301 ↗
24. 10.1371/journal.pone.017196910.1371/journal.pone.0171969 ↗
25. 10.1155/2015/49746210.1155/2015/497462 ↗
26. 10.1039/C7FO00992E10.1039/C7FO00992E ↗
27. 10.3892/or.2016.479810.3892/or.2016.4798 ↗
28. 10.18632/oncotarget.1606610.18632/oncotarget.16066 ↗
29. 10.3390/ijms15122370510.3390/ijms151223705 ↗
30. 10.1371/journal.pone.007211510.1371/journal.pone.0072115 ↗
31. 10.1002/mnfr.20100041910.1002/mnfr.201000419 ↗
32. Cam A, de Mejia EG. RGD-peptide lunasin inhibits PI3-kinase/Akt-mediated NF-κ B activation in human and murine macrophages through interaction with alpha v beta 3 integrins. FASEB J. 2012;56:1569–1581.
33. 10.1016/j.joca.2009.09.00210.1016/j.joca.2009.09.002 ↗